La FDA retira la aprobación del medicamento para linfoma Ukoniq (umbralisib) debido a que su perfil de riesgo supera sus potenciales beneficios
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | article |
| Language: | Spanish |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/20.500.12008/37370 |
| Tags: |
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!